Recently discovered properties of aspirin may be doubly helpful in bipolar disorders

Medical Hypotheses

Volumn 82, Issue 5, 2014, Pages 640-641

  Fond, Guillaume ^a   Girerd, Nicolas ^b   Clavel, Françoise ^c   Tamouza, Ryad ^a   Leboyer, Marion ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 6; LIPOXIN; LITHIUM; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; BIPOLAR DISORDER; BREAST CANCER; CARDIOVASCULAR RISK; DEPRESSION; ENZYME INHIBITION; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; LETTER; MICROGLIA; NERVE DEGENERATION; THEORETICAL MODEL;

ASPIRIN; BIPOLAR DISORDER; HUMANS; MODELS, THEORETICAL;

EID: 84897115602     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.02.028     Document Type: Letter

References (14)

1. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., et al. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J Affect Disord 2012, 141:1-10.
2. Cipollone F., Patrignani P., Greco A., Panara M.R., Padovano R., Cuccurullo F., et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997, 96:1109-1116.
3. Choi S.H., Aid S., Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 2009, 30:174-181.
4. Stolk P., Souverein P.C., Wilting I., Leufkens H.G., Klein D.F., Rapoport S.I., et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010, 82:9-14.
5. Crump C., Sundquist K., Winkleby M.A., Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013, 70:931-939.
6. Munkholm K., Vinberg M., Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013, 144:16-27.
7. Gilroy D.W. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukot Essent Fatty Acids 2005, 73:203-210.
8. Medeiros R., Kitazawa M., Passos G.F., Baglietto-Vargas D., Cheng D., Cribbs D.H., et al. Aspirin-triggered lipoxin a4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol 2013, 182:1780-1789.
9. Hussain M., Javeed A., Ashraf M., Zhao Y., Mukhtar M.M., Rehman M.U. Aspirin and immune system. Int Immunopharmacol 2012, 12:10-20.
10. Cronstein B.N., Montesinos M.C., Weissmann G. Sites of action for future therapy: an adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFkappaB knockout mice. Osteoarthritis Cartilage 1999, 7:361-363.
11. Taubert D., Berkels R., Grosser N., Schroder H., Grundemann D., Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004, 143:159-165.
12. Grilli M., Pizzi M., Memo M., Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 1996, 274:1383-1385.
13. Basselin M., Ramadan E., Chen M., Rapoport S.I. Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites. Neurochem Res 2011, 36:139-145.
14. Gao X.R., Adhikari C.M., Peng L.Y., Guo X.G., Zhai Y.S., He X.Y., et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol 2009, 61:1505-1510.